These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 17532642)

  • 1. AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease.
    Gasmi M; Brandon EP; Herzog CD; Wilson A; Bishop KM; Hofer EK; Cunningham JJ; Printz MA; Kordower JH; Bartus RT
    Neurobiol Dis; 2007 Jul; 27(1):67-76. PubMed ID: 17532642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys.
    Kordower JH; Herzog CD; Dass B; Bakay RA; Stansell J; Gasmi M; Bartus RT
    Ann Neurol; 2006 Dec; 60(6):706-15. PubMed ID: 17192932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease.
    Herzog CD; Brown L; Gammon D; Kruegel B; Lin R; Wilson A; Bolton A; Printz M; Gasmi M; Bishop KM; Kordower JH; Bartus RT
    Neurosurgery; 2009 Apr; 64(4):602-12; discussion 612-3. PubMed ID: 19349823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys.
    Herzog CD; Dass B; Holden JE; Stansell J; Gasmi M; Tuszynski MH; Bartus RT; Kordower JH
    Mov Disord; 2007 Jun; 22(8):1124-32. PubMed ID: 17443702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120).
    Herzog CD; Brown L; Kruegel BR; Wilson A; Tansey MG; Gage FH; Johnson EM; Bartus RT
    Neurobiol Dis; 2013 Oct; 58():38-48. PubMed ID: 23631873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
    Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
    Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease.
    Ramaswamy S; McBride JL; Herzog CD; Brandon E; Gasmi M; Bartus RT; Kordower JH
    Neurobiol Dis; 2007 May; 26(2):375-84. PubMed ID: 17336076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease.
    Bartus RT; Brown L; Wilson A; Kruegel B; Siffert J; Johnson EM; Kordower JH; Herzog CD
    Neurobiol Dis; 2011 Oct; 44(1):38-52. PubMed ID: 21704161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopaminergic neuroprotection by neurturin-expressing c17.2 neural stem cells in a rat model of Parkinson's disease.
    Liu WG; Lu GQ; Li B; Chen SD
    Parkinsonism Relat Disord; 2007 Mar; 13(2):77-88. PubMed ID: 16963309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transplantation of bone marrow stromal cells containing the neurturin gene in rat model of Parkinson's disease.
    Ye M; Wang XJ; Zhang YH; Lu GQ; Liang L; Xu JY; Chen SD
    Brain Res; 2007 Apr; 1142():206-16. PubMed ID: 17336273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease.
    Gasmi M; Herzog CD; Brandon EP; Cunningham JJ; Ramirez GA; Ketchum ET; Bartus RT
    Mol Ther; 2007 Jan; 15(1):62-8. PubMed ID: 17164776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Issues regarding gene therapy products for Parkinson's disease: the development of CERE-120 (AAV-NTN) as one reference point.
    Bartus RT; Herzog CD; Bishop K; Ostrove JM; Tuszynski M; Kordower JH; Gasmi M
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S469-77. PubMed ID: 18267286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional reinnervation from remaining DA terminals induced by GDNF lentivirus in a rat model of early Parkinson's disease.
    Brizard M; Carcenac C; Bemelmans AP; Feuerstein C; Mallet J; Savasta M
    Neurobiol Dis; 2006 Jan; 21(1):90-101. PubMed ID: 16084732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ex vivo gene delivery of GDNF using primary astrocytes transduced with a lentiviral vector provides neuroprotection in a rat model of Parkinson's disease.
    Ericson C; Georgievska B; Lundberg C
    Eur J Neurosci; 2005 Dec; 22(11):2755-64. PubMed ID: 16324109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum.
    Herzog CD; Dass B; Gasmi M; Bakay R; Stansell JE; Tuszynski M; Bankiewicz K; Chen EY; Chu Y; Bishop K; Kordower JH; Bartus RT
    Mol Ther; 2008 Oct; 16(10):1737-44. PubMed ID: 18728639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of GDNF in neuronal protection against 6-OHDA-induced parkinsonism following intracerebral transplantation of fetal kidney tissues in adult rats.
    Borlongan CV; Zhou FC; Hayashi T; Su TP; Hoffer BJ; Wang Y
    Neurobiol Dis; 2001 Aug; 8(4):636-46. PubMed ID: 11493028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway.
    Deumens R; Blokland A; Prickaerts J
    Exp Neurol; 2002 Jun; 175(2):303-17. PubMed ID: 12061862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant adeno-associated viral vectors bring gene therapy for Parkinson's disease closer to reality.
    Muramatsu S; Wang L; Ikeguchi K; Fujimoto K; Nakano I; Ozawa K
    J Neurol; 2002 Sep; 249 Suppl 2():II36-40. PubMed ID: 12375062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating "clinical proof-of-concept" for AAV-neurturin (CERE-120) in Parkinson's disease.
    Bartus RT; Baumann TL; Brown L; Kruegel BR; Ostrove JM; Herzog CD
    Neurobiol Aging; 2013 Jan; 34(1):35-61. PubMed ID: 22926166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treadmill exercise suppresses nigrostriatal dopaminergic neuronal loss in 6-hydroxydopamine-induced Parkinson's rats.
    Yoon MC; Shin MS; Kim TS; Kim BK; Ko IG; Sung YH; Kim SE; Lee HH; Kim YP; Kim CJ
    Neurosci Lett; 2007 Aug; 423(1):12-7. PubMed ID: 17644250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.